Compremium’s noninvasive Quantis CVP (central venous pressure) measurement device joined the FDA’s Total Product Life Cycle Advisory Program (TAP) after earning Breakthrough Device designation in January 2026. The FDA designed TAP to “help spur more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health” and expedite patient access…
The post Regulatory tips from a breakthrough noninvasive device startup appeared first on Medical Design and Outsourcing.